Trial Profile
Integrated Pilot Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pepinemab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics
- 03 Oct 2023 Planned End Date changed from 26 Jul 2023 to 26 Jul 2025.
- 03 Oct 2023 Planned primary completion date changed from 26 Jul 2023 to 26 Jul 2024.
- 13 Sep 2022 Planned number of patients changed from 36 to 50.